Skip to main
PSTV

PSTV Stock Forecast & Price Target

PSTV Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Plus Therapeutics Inc is progressing positively in its drug development initiatives, particularly with its lead candidate, rhenium (186Re) obisbemeda, which targets central nervous system cancers, alongside advancements in the CNSide CSF assay platform. The company has secured a significant $18 million grant from the Cancer Prevention and Research Institute of Texas to study leptomeningeal metastases, highlighting its potential for funding and growth in this critical area of oncology. Additionally, expanded laboratory licenses for its CNSide Diagnostics in various states and operational enhancements are set to facilitate increased test volumes and adoption, further strengthening Plus Therapeutics' strategic positioning in the CNS oncology market.

Bears say

Plus Therapeutics Inc faces several fundamental risks that contribute to a negative outlook on its stock. Key concerns include the potential failure of its product candidates, particularly rhenium (186Re) obisbemeda, to demonstrate safety and efficacy in clinical trials, which may hinder future regulatory approvals and commercial viability. Additionally, challenges related to obtaining suitable reimbursement and increasing competition in the pharmaceutical sector further exacerbate the uncertain outlook for the company's financial performance.

PSTV has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Plus Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Plus Therapeutics Inc (PSTV) Forecast

Analysts have given PSTV a Strong Buy based on their latest research and market trends.

According to 4 analysts, PSTV has a Strong Buy consensus rating as of Dec 26, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Plus Therapeutics Inc (PSTV)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.